Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

rTMS as an Intervention for Levodopa-induced Dyskinesia

NCT: NCT06570824 · RECRUITING

NCT IDNCT06570824
StatusRECRUITING
Start Date2024-08-22
Completion2027-12-01
SponsorDanish Research Centre for Magnetic Resonance (OTHER)
First posted
Last updated

Brief Summary

The proposed study investigates the use of repetitive transcranial magnetic stimulation (rTMS) as a treatment for levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD). Specifically, the study aims to determine whether patterned stimulation of the pre-supplementary motor area (pre-SMA) can delay the onset of LID after levodopa intake and reduce LID severity in PD patients. This study will provide critical insights into potential targets for rTMS treatment, optimal rTMS parameters, and the mechanisms underlying LID in Parkinson's disease.

Frequently Asked Questions

What is rTMS as an Intervention for Levodopa-induced Dyskinesia?

rTMS as an Intervention for Levodopa-induced Dyskinesia is a clinical trial registered under NCT06570824. Current status: RECRUITING.

What is the status of NCT06570824?

The current status of NCT06570824 (rTMS as an Intervention for Levodopa-induced Dyskinesia) is: RECRUITING.

When did rTMS as an Intervention for Levodopa-induced Dyskinesia start?

rTMS as an Intervention for Levodopa-induced Dyskinesia started on 2024-08-22.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.